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Abstract: Background: Fisetin, a flavonol profusely found in vegetables and fruits, exhibited a
myriad of properties in preclinical studies to impede cancer growth. Purpose: This study was
proposed to delineate molecular mechanisms through analysing the modulated expression of various
molecular targets in HeLa cells involved in proliferation, apoptosis and inflammation. Methods: MTT
assay, flow cytometry, nuclear morphology, DNA fragmentation and Annexin–Pi were performed
to evaluate the anti-cancer potential of fisetin. Furthermore, qPCR and proteome profiler were
performed to analyse the expression of variety of gene related to cell death, cell proliferation, oxidative
stress and inflammation and cancer pathways. Results: Fisetin demonstrated apoptotic inducing
ability in HeLa cells, which was quite evident through nuclear morphology, DNA ladder pattern,
decreased TMRE fluorescent intensity, cell cycle arrest at G2 /M and increased early and late apoptosis.
Furthermore, fisetin treatment modulated pro-apoptotic genes such as APAF1, Bad, Bax, Bid and
BIK at both transcript and protein levels and anti-apoptotic gene Bcl-2, BIRC8, MCL-1, XIAP/BIRC4,
Livin/BIRC7, clap-2/BIRC3, etc. at protein levels to mitigate cell proliferation and induce apoptosis.
Interestingly, the aforementioned alterations consequently led to an elevated level of Caspase-3,
Caspase-8 and Caspase-9, which was found to be consistent with the transcript and protein level
expression. Moreover, fisetin downregulated the expression of AKT and MAPK pathways to avert
proliferation and enhance apoptosis of cancer cells. Fisetin treatment also improves oxidative stress
and alleviates inflammation by regulating JAK-STAT/NF-kB pathways. Conclusion: Together, these
studies established that fisetin deters human cervical cancer cell proliferation, enhances apoptosis
and ameliorates inflammation through regulating various signalling pathways that may be used as a
therapeutic regime for better cancer management.

iations.
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1. Introduction
Cancer is a pleiotropic disease caused by unorchestrated and undesirable cell reproduction. It is the second leading cause of mortality worldwide, followed by cardiac ailments.
The undesirable side effects of various conventional treatments, including chemotherapy
and chemopreventive agents such as Tamoxifen aspirin, sulindac, Raloxifene, etc. along
with lack of specificity, confines the generous use of these treatments; therefore, researchers
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along with lack of specificity, confines the generous use of these treatments; therefore,
researchers in the last two decades have shifted their focus towards phytochemicals
(plant-derived chemopreventive agents) that exhibit a differential response against transin the last two decades have shifted their focus towards phytochemicals (plant-derived
formed cells with a safer profile [1,2]. Comprehensive epidemiological data demonstrate
chemopreventive agents) that exhibit a differential response against transformed cells with
a strong correlation between a diet rich in fruits and vegetables and the reduced threat of
a safer profile [1,2]. Comprehensive epidemiological data demonstrate a strong correlation
carcinogenesis, as they are enriched with polyphenols (which contains multiple phenolic
between a diet rich in fruits and vegetables and the reduced threat of carcinogenesis, as
groups) [3,4].
they are enriched with polyphenols (which contains multiple phenolic groups) [3,4].
Dietary polyphenols possess a repertoire of biological properties with remarkable
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Fisetin demonstrates anti-metastatic properties by suppressing phosphoinositide 3kinase/Akt [PI3K/Akt], NF-kB, and JNK signalling pathways in prostate cancer cells and
human cervical cancer HeLa cells [4,16]. It acts as an inhibitor of PI3K/Akt, which is found
to be overexpressed in different types of cancers to impede cancer growth of prostate, pancreas and lung cancer [10]. Fisetin enhances apoptosis in different cell lines by changing the
quotient of Bax/Bcl-2 and upregulation of Caspase 3, 8 and 9 activities. Fisetin also inhibits
cell proliferation by arresting cell cycle at G2/M phase in A 431 cells (human epidermoid
carcinoma) [17–22]. Moreover, fisetin also possesses a potent protective property as it
relieves the oxidative stress and inflammation by upregulating different enzymes such as
glutathione peroxidase, catalase, superoxide dismutase, etc., and decreases the expression
of pro-inflammatory cytokines or increases anti-inflammatory cytokines [23–25].
This study is aimed to investigate anti-proliferative, anti-apoptotic, antioxidant and
anti-inflammatory properties with an insight into the molecular mechanism involving
signalling pathways that are being modulated by fisetin.
2. Results
2.1. Fisetin Induces Morphological Changes and Inhibits Proliferation of HeLa Cells
The MTT test was employed to investigate fisetin’s cytotoxic effects on HeLa cell
proliferative capacity. Fisetin-treated HeLa cells from 1–70 µM for 24 and 48 h displayed
an inhibitory effect on growth of HeLa cell both with increasing time and concentrationdependent manner which ranged from 4–32% in 24 h and 18–67% in 48 h (p < 0.001). The
IC50 value was 50 µM at 48 h. Fisetin did not show any significant change in cell viability
of AC-16 (cardiomyocyte; normal cell line), thus illustrating differential cytotoxic, hence a
safer profile (Figure 1B). All the experiments were repeated at least thrice. The morphology
of the treated cells was different in comparison to the control, and they were rounded off
and detached from the surface. The percentage of dead cells at 20, 30 and 50 µM increased
both in time and dose-dependent manner (Figure 1C).
2.2. Fisetin Changes Nuclear Morphology of HeLa Cells
To evaluate the changes in nuclear morphology, treated cells with 20, 30 and 50 µM
of fisetin were stained with DAPI. DAPI staining demonstrated that fisetin treated cells
revealed nuclear condensation, fragmentation and apoptotic body formation, which was
augmented with both concentration and time-point modes (Figure 1D).
2.3. Fisetin Leads DNA Fragmentation
To evaluate the mechanism of fisetin-induced cytotoxicity, DNA fragmentation assay
was performed. DNA analysis of the fisetin-treated HeLa cells (20 µM and 50 µM) for 48 h
demonstrated that fisetin efficiently reduces DNA integrity and consequently induces DNA
ladder formation in treated cells in a dose-dependent manner as evident via agarose gel
electrophoresis. In contrast, the DNA of the control cells remained intact (Figure 1E).
2.4. Fisetin Encourages G2/M Arrest and Modulates Cell Cycle Regulatory Genes
Fisetin affects the proliferation of HeLa cells via cell cycle arrest and causes apoptosis.
Treated cells (20, 30 and 50 µM) for 24 and 48 h and the untreated control were subjected
to flow cytometry. Treated cells with 20, 30 and 50 µM fisetin resulted in a significant
accumulation of cells in G2/M phase (Figure 2A). It has increased from 10.1% to 16.2%,
18.9%, and 25.1%, respectively in 24 h while in 48 h the proportion of G2/M arrested cells
increased to 30.9%, 36.2%, 56.2% at 20 µM, 30 µM and 50 µM, respectively. Simultaneously,
a significant proportion of cells was built up in Go/G1 phase at 50 µM of fisetin at 48 h
(Figure 2B,C).
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µM only. Fisetin illustrated downregulation of CCNB1, CCNB2, CCNE2, CDK2 and, CDK4
corresponding to G2/M phase arrest and TERT enzyme, which deters cell proliferation. In
contrast, PTPRR, FOXO1, FOXO3 expression was elevated. PTPRR acts as an ERK/MAPK
4 ofapoptotic
20
pathway inhibitor, while the latter two play a significant role in the extrinsic
pathway by upregulating FasL and TRAIL (pro-apoptotic factors) (Table 1) (Figure 2D).
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2.5. Fisetin Shows Early Apoptosis on HeLa Cells
Annexin V/PI double staining on treated HeLa cells at 20, 30 and 50 µM for 48 h
displayed an increase in the early and late apoptotic cells, whereas the percentage of
live cells showed a decreasing trend. Fisetin treatment resulted in the augmentation of
both early and late apoptotic cell populations. Early apoptotic cell population was found
to be increased from 0.35% to 13%, 13.6% and 17%, likewise, PI-stained post apoptotic
cells increased in proportion from 1.34% to 3.71%, 6.42% and 6.71% at 20, 30 and 50 µM,
respectively. Therefore, Annexin–PI staining established the apoptosis-inducing property
of fisetin in HeLa cells (Figure 3A,B).
2.6. Fisetin Decreases TMRE Fluorescent Intensity
Altered mitochondrial potential is one of the triggers for apoptotic induction. The
mitochondrial membrane potential of the untreated control was compared with the fisetintreated cells to investigate whether fisetin induces mitochondrial dysfunction to release
cyt-c. After staining the treated and untreated control cells with TMRE for half an hour,
washed cells were examined under an inverted fluorescent microscope at ×40. A bright
red fluorescent aggregate was observed in the mitochondrial matrix of untreated control,
whereas the fluorescent intensity was found to be decreasing with the increasing concentration of fisetin (20, 30 and 50 µM) treated cells from 74% to 70% and 54% (Figure 3C,D).
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by fluorescent microscope. (D) Graph representing TMRE fluorescence of treated HeLa cells with
fisetin 20, 30 and 50 µM for 48 h, which exhibited reduction in mitochondrial membrane potential
from 81% to 64% and 54%, respectively, in comparison with the untreated control. Data are presented
as the mean ± standard deviation of three independent experiments. Two-way ANOVA * = p < 0.05;
** = p < 0.01, *** p < 0.001.

2.7. Fisetin Activates Extrinsic and Intrinsic Pathways
The apoptosis-inducing property of fisetin was substantiated by detecting an alteration
in the expression of various genes pertaining to death receptor and the intrinsic (mitochondrial pathway) apoptotic pathway. Fisetin treated cells with 20 and 50 µM for 48 h
displayed upregulation of various pro-apoptotic genes, whereas anti-apoptotic genes were
downregulated. The expression of multiple receptors and ligands involved in extrinsic
pathways such as FAS, FASL, CARD6, CARD9, CRADD, DEDD, FADD, TNF, TNFRSFS10A
and TNFRSFS10B increased, which, as well as the upregulation of Caspases8Ap2 and Caspase8, are indicative of the extrinsic pathway of apoptosis. Genes of BCL2 family such
as BCL10, BCL2A1, BCL2L1, BCL2L13, BCL2L2, BAD, BAK1 and BAX, BID, BOK, HTRA2,
PYCARD, RIPK1, RIPK2 and BID were also upregulated significantly, and the apoptotic
inhibitory proteins such as Bcl-2, MCL1, BIRC5 and NAIP were discovered to be under
expressed. Caspases such as caspase 1, caspase 2, caspase 3, caspase 4, caspase 6, caspase 7 and
caspase 9 also exhibited upregulation along with APAF1 at the transcript level, therefore
signifying an intrinsic pathway (Table 1) (Figure 4A).

ses8Ap2 and Caspase8, are indicative of the extrinsic pathway of apoptosis. Genes of BCL2
family such as BCL10, BCL2A1, BCL2L1, BCL2L13, BCL2L2, BAD, BAK1 and BAX, BID,
BOK, HTRA2, PYCARD, RIPK1, RIPK2 and BID were also upregulated significantly, and
the apoptotic inhibitory proteins such as Bcl-2, MCL1, BIRC5 and NAIP were discovered
to be under expressed. Caspases such as caspase 1, caspase 2, caspase 3, caspase 4, caspase 6,
Int. J. Mol. Sci. 2022, 23, 1707
caspase 7 and caspase 9 also exhibited upregulation along with APAF1 at the transcript level,
therefore signifying an intrinsic pathway (Table 1) (Figure 4A).
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2.8. Fisetin Modulates Expression of Various Pro- and Anti-Apoptotic Proteins
Fisetin treated HeLa cells showed dose-dependent modulation of different proteins
involved in apoptosis, a trend that concords with the transcript expression. The expression
of Bad, Bax, Bid, Bim, P21, p53, p27, TNFRF, TNFSFS (ligand), cyt-c, Fas, Fas ligand, HSP27,
IGFBP-1 to IGFBP-4, TNFRII, TNF ALPHA, TNF BETA, TRAIL R1 to TRAIL R4, caspase3 and caspase-8 were upregulated. In contrast, the pro-survival proteins such as Bcl-2,
BCL-w, clap-2, HSP70, LIVIN, Survivin and XIAP expression were found to be significantly
decreased (Figure 4B,C).
2.9. Fisetin Elevates Caspase-3, Caspase-8 and Caspase-9 Activity
Fisetin-treated cells were analysed for caspase-3, -8 and -9 expression by a fluorometric
assay. Fisetin treatment at 20, 30 and 50 µM for 48 h showed comparative dose-dependent
elevation in caspase- 3 and Caspase-9 activity from 2.3 to up to 4.4-fold and from 2.5 to
little more than 4.5-fold, respectively, whereas Caspase-8 displayed an upregulation of up
to 2.9-fold only (Figure 4D).
2.10. Fisetin Ameliorates Oxidation Stress in HeLa Cells by Upregulating GSH Activity
Fisetin-treated cells (20, 30, and 50 µM for 48 h) exhibited upregulation in GSH level
to 1.8, 2.4, and 3-fold, respectively, compared with the DMSO control (Figure 5A).
2.11. Fisetin Alleviates Inflammation in HeLa Cells
Carcinogenesis induced by inflammation correlates with oxidative stress, imbalanced
cytokine production and a modulated NF-κB signalling pathway. Fisetin-treated HeLa cells
at 50 µM for 48 h demonstrated downregulation in the expression of various inflammatory
cytokine proteins such as IL-1α, IL-1β, IL-4, IL-7, IL-11, IL-16, IL-12p70, MIG, MCP-1,
MCP-2, MIP-1β, MIP-1γ, MCF, I-309 and EOTAXIN compared with untreated control cells,
whereas the expression of IL-10 and IL-13 were reduced (Figure 5B,C).
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pathway such as MAPK1, MAK14, MAP2K1, MAP2K6 and ELK 1 along with AKT/MTOR
pathway genes such as AKT2, MTOR, PIK3C2B and PIK3CB. In contrast, the expression of ATM, ATF2, and VHL was increased, consequently decreasing MYC expression
(Figure 2D). Moreover, fisetin modifies various phosphorylated proteins associated with
cancer pathways. Fisetin (50 µM) treatment altered the expression of phosphorylated proteins involved in MAPK, AKT, JAK-STAT and NF-kB. MAPK pathway genes at the protein
level exhibiting downregulation in expression are RSK1 (P-Ser380) and Raf-1 (P-Ser301),
whereas p38 (P-Thr180/Tyr182) and P53 (P-Ser15) were found to be upregulated. The
phosphorylated protein of the AKT pathway, such as GSK3a (p-ser21), GSK3b (p-ser9),
MTOR (p-ser2448), PRAS 40 (p-Ther246), BAD (p-ser112), PTEN (p-ser380), AKT (p-ser473),
AMPKa (P-Thr172), RPS6 (P-Ser235/236) and 4E-BP1 (P-Thr36) showed reduced expression
while p27 (P-Thr198) was increased compared with the control. Similarly, fisetin exhibited its potential anti-inflammatory action by downregulating both JAK-STAT and NF-kB
pathways. The phosphorylation level of various molecular targets was altered, such as Src
(P-Tyr419), STAT1 (P-Ser727), STAT2 (P-Tyr689), STAT3 (P-Tyr705), STAT5 (P-Tyr694), TYK2
(P-Tyr1054), HDAC4 (P-Ser632), NF-kB (P-Ser536), TAK1 (P-Ser412) and TBK1 (P-Ser172).
HDAC2 (P-Ser394) phosphorylation was also reduced marginally (Figure 6A,B).
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whose impressive anticancer activity was established by an overwhelming number of studies [19,26–28]. Potential anticancer properties exhibited by fisetin include anti-proliferation,
tumour growth arrest by the modulation of essential factors that regulate the cell cycle and
apoptosis. The apoptosis-inducing property of fisetin in transformed cells is the key feature
of a potential chemopreventive agent. The current study analysed and verified that fisetin
inhibits proliferation and acts as an apoptotic inducer in HeLa cells in in vitro conditions.
This study shows that fisetin reduces the viability of HeLa cells in both concentration and
time-dependent modes, the IC50 value was determined as 50 µM at 48 h. Consistent with
other studies that demonstrated similar results, IC50 value was documented in previous
studies to be IC50 of 52 ± 0.9 and 36 ± 0.5 µM at 24 and 48 h, respectively. In lung adenocarcinoma, A549 cell line was 58 µM in 48 h [14], in breast adenocarcinoma, MDA-MB-231
-78 and -68 µM in 24 and 48 h, respectively [16], in Squamous carcinoma, A431 58 µM
and 50 µM in 24 and 48 h [20]. Additionally, fisetin illustrated differential cytotoxic as it
did not exhibit cytotoxicity towards AC-16 cells (Figure 1B). Treated cell morphologies
were distinct compared with the DMSO control as they were rounded off and floating in
the media. The percentage of dead cells at 20, 30 and 50 µM increased both in time and
dose-dependent manner (Figure 1C). The safer profile of fisetin and other polyphenols such
as quercetin, luteolin in normal cell lines and animal models was reported in other studies
as well [13,29,30]. The differential cytotoxic action of fisetin towards tumour/cancer cells
marks it as an ideal drug candidate.
Nuclear morphological alteration followed by fisetin treatment (20, 30 and 50 µM) of
HeLa cells through DAPI staining showed characteristics of apoptotic nuclear morphology
that proves the apoptosis-inducing property of fisetin, which showed an increasing trend
both in the dose and time-dependent manner. The treated cells displayed membrane
blebbing, chromatin condensation and apoptotic body formation, whereas no significant
change was observed in the nucleus of untreated control cells. Similar results were reported
in glioma, HeLa cells, etc. (Figure 1D) [13,31,32]. Furthermore, fisetin treatment at 20,
30 and 50 µM for 48 h led to inter-nucleosomal degradation of DNA, which upon gel
electrophoresis demonstrated a ladder pattern formation. The degradation was found to
be increasing with increasing concentration, whereas the DNA of the untreated control
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did not undergo any degradation (Figure 1E). Flavonoids such as fisetin, chrysin and
quercetin were shown to trigger apoptosis through DNA fragmentation in different cell
lines [3,32,33]. The DNA content of treated cells at 0, 20, 30 and 50 µM was ascertained by
flow cytometry to illustrate the anti-proliferative property of fisetin, as cell cycle checkpoints
are the regulatory points for cell growth. Fisetin treatment in HeLa cells demonstrated
an accumulation of cells that was dose dependent in G2/M phase from 10.1% to 16.2%,
18.9% and 25.1%, respectively, in 24 h. In comparison, at 48 h, the proportion of G2/Marrested cells increased to 30.9%, 36.2% and 56.2% at 20, 30 and 50 µM, respectively, and a
significant proportion of cells was also built up in Go/G1 phase at 50 µM of fisetin at 48 h
(Figure 2A–C). Several reports confirmed that flavonoids exhibit their anti-proliferative
property by arresting cell cycle at G2/M [33,34]. This study aligns with the previous studies
which confirmed fisetin causes G2/M cell cycle arrest in A431 cells and hepatocellular
carcinoma HepG2 cell line while Go/G1 arrest in bladder cancer cell lines T24 and prostate
cancer cell line PC3, LNCa [16,35]. In addition, G2 /M arrest was further established at
molecular level by analysing the transcript-level expression of different cell cycle regulatory
genes. Molecular-level study results demonstrate consistency with the result found in flow
cytometry as fisetin treatment downregulated the expression of CCNB1, CCNB2, CCNE2,
CDK2, CDK4 and TERT that corresponds to G2/M phase arrest [18,19]. hTERT is responsible
for maintaining the integrity and stability of linear chromosome. Therefore, its inhibition
by polyphenols aids in halting cell cycle progress and preventing cell proliferation. In
addition, fisetin treatment led to the elevated expression of PTPRR, FOXO 1 and FOXO
3 [Table 1]. FOXO1/3 are tumour suppressor genes [TSG] that upregulate transcription
of various genes involved in anti-survival pathways such as FasL and TRAIL, and DNA
repair and cell cycle regulation. Expression of these TSGs was reported to be decreased in
several cancer cell lines. PTPRR acts as an inhibitor of the ERK/MAPK pathway. therefore
helping to deter cell propagation [13,30,36–38] (Figure 2D).
Assumption of fisetin-mediated apoptosis was further evaluated by Annexin V/Propidium
Iodide double staining. After 48 h of fisetin treatment, the early apoptotic cell population
was found to be increased from 2.77% to 13%, 13.6% and 17%, likewise, the PI-stained
post apoptotic cell population increased in a dose-dependent manner from 1.14% to 3.71%,
6.42% and 6.71% at 20, 30 and 50 µM, respectively [14,19] (Figure 3A,B). Furthermore,
apoptosis was confirmed through disruption of mitochondrial potential using TMRE
dye. The fluorescent intensity was evidenced to be decreased from 75% to 70% and 54%
with the increasing concentration of fisetin-treatment i.e. 20, 30 and 50 µM respectively,
compared to untreated control. Earlier studies confirmed that fisetin leads to depolarization
of the mitochondrial membrane to induce apoptosis in the gastric cancer cell and HeLa
cells [19,30,32] (Figure 3C,D).
Anti-survival and pro-survival genes are principal molecules pertaining to the regulation of cell death pathways, and their aberrant manifestation drives the cells towards tumorigenesis; therefore, respective modulation of these genes via chemopreventive agents can be
crucial to mitigate cancer growth and provide a safer treatment opportunity [14,19,20,30].
Fisetin-treated cells with 20 and 50 µM for 48 h resulted in upregulation of various proapoptotic genes, whereas anti-apoptotic genes were downregulated. The expression of
multiple receptors and ligands involved in extrinsic pathways such as FAS, FASL, CARD6,
CARD9, CRADD, DEDD, FADD, TNF, TNFRSFS10A and TNFRSFS10B increased, that, as
well as the upregulation of Caspases8Ap2 and Caspase8, are indicative of extrinsic pathways
of apoptosis. Genes of the BCL2 family such as BCL10, BCL2A1, BCL2L1, BCL2L13, BCL2L2,
BAD, BAK1 and BAX, BID, BOK, HTRA2, PYCARD, RIPK1, RIPK2, and BID were also
upregulated significantly, and the apoptotic inhibitory proteins such as BCL2, MCL1, BIRC5,
and NAIP were discovered to be under regulated. Both initiator and executioner caspases
involved in intrinsic pathways such as caspase 1, caspase 2, caspase 3, caspase 4, caspase 6,
caspase 7, and caspase 9 also exhibited upregulation along with APAF1 at the transcript
level, therefore signifying an intrinsic pathway (Figure 4A). In addition, concordant with
the transcript level expression, apoptotic proteins also exhibited an increasing trend in
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concentration-dependent manner such as the expression of Bad, Bax, Bid, Bim, P21, p53,
p27, TNFRF, TNFSFS (ligand), cyt-c, Fas, Fas ligand, HSP27, TNFRII, TNF α, TNF β, TRAIL
R1 to TRAIL R4, caspase-3 and caspase-8 were upregulated, whereas the anti-apoptotic
proteins such as Bcl-2, BCL-w, clap-2, HSP70, LIVIN, Survivin and XIAP expression were
found to be significantly decreased (Table 1). Similar results were previously described
by fisetin on different cell lines [21,22,27,39,40] (Figure 4B,C). Modulation in expression
of aforementioned molecules at transcript and protein level was also induced by other
flavonoids [13,30]. Furthermore, fisetin-mediated transcript and protein level increases in
caspase 3, 8 and 9 expressions were validated by biochemical activity of these caspases. In
addition, concordant with mRNA and protein level, the biochemical activity of caspase 3, 8
and 9 (at 20, 30 and 50 µM) was increased by fisetin ≤ 4, 3.5 and 5-fold, respectively [19,27]
(Figure 4D). Apoptosis is mediated by various caspases, of which Caspase 8 is involved in
the extrinsic pathway along with death receptors, while caspase 9 in the intrinsic pathway
and expression of both the caspases was increased by fisetin along with Fas, Fas ligand,
HSP27, TNFRII, TNF α, TNF β and TRAIL R1 to TRAIL R4. Caspase 3 is the executioner
caspase, which is common in both extrinsic and intrinsic pathways, therefore confirming
that fisetin mediates apoptosis via both death receptor and mitochondrial-mediated pathways. The result of this study are consistent with available reports that have documented
that fisetin induces apoptosis by increasing the activity of caspase 3, 8 and 9 [19,33,41].
The anti-oxidative system protects organisms from the impairment initiated by oxidative stress consequently caused by free radicals. Disparity between the oxidation–
antioxidation system has been reported in various cancers, including cervical cancer [42,43].
Various reports established a strong association between oxidative stress and inflammation. Chronic inflammation produces a variety of ROS (free radicals) such as superoxide
(O2 − ), singlet oxygen (1 O2), nitric oxide (NO) and hydrogen peroxide (H2 O2 ), which were
established to cause oxidative stress and genetic damage to the cervical epithelium, which
leads to their conversion into cancer cells [41,44,45]. Therefore, inflammation and oxidative
stress are viewed as two of the major factors that lead to carcinogenesis.
Various endogenous enzymes such as superoxide dismutase (SOD), glutathione peroxidase (GTPx), catalase (CAT) and glutathione transferase [GST] protects the cells from
oxidative stress as they can scavenge free radicals, thereby regulating the activity of various enzymes and proteins [44]. Flavonoids such as myricetin, quercetin and fisetin have
been reported to increase the GSH level in various cancer cell lines [46–48]. A significant
decrease in GSH levels has been detected in cervical cancer patients compared with healthy
controls [44,49]. The treatment with fisetin of HeLa cells showed an increase in GSH
level ≥ 3-fold, improving antioxidant stress (Figure 5A). It has been well established that
increased ROS levels owing to inflammation trigger the production of pro-inflammatory
cytokines, such as IL-1b, the IL-6 by activating NF-KB and JAK-STAT pathways [50]. In
the current study, fisetin treatment significantly reduced the expression of various proinflammatory cytokines and chemokines at protein levels such as IL-1α, IL-1β, IL-7, IL-11
IL-16, IL-12p70, MIG, MCP-1, MCP-2, MIP-1β, MIP-1γ, MCF, I-309 and EOTAXIN compared with untreated control cells. In comparison, the expression of anti-inflammatory
cytokines such as IL-10 and IL-13 were found to be upregulated (Table 1). Expression
of TNF-α, s TNF RI and s TNF RII was also increased because TNF-α acts as a pro and
anti-inflammatory cytokine and plays a significant role in inducing apoptosis (Figure 5B,C).
Consistent with this finding, several studies documented that IL-10 impedes NF-κB signalling and inhibits pro-inflammatory cytokine production [23–25,51–53]. Probably, fisetinmediated upregulated expression of IL-10 and IL-13 (anti-inflammatory) cytokines inhibit
NF-kB pathways by reducing the phosphorylation level of different proteins related to the
pathway. Repressed NF-kB pathways directly or indirectly reduce the expression of various
pro-inflammatory cytokines. Furthermore, fisetin treatment elevated total glutathione
levels (GSH), which may further reduce inflammation by scavenging ROS and free radicals.
Fisetin treatment significantly modulated the phosphorylation of various molecular
targets of NF-κB and JAK-STAT pathway to reduce inflammation such as Src (P-Tyr419), NF-
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kB (P-Ser536), TAK1 (P-Ser412), TBK1 (P-Ser172) and HDAC2 (P-Ser394). Phosphorylation
was also slightly reduced (Figure 6A,B). In line with this study, Luo et al. established that
inhibiting the NF-κB pathway led to tumour regression through TNF-α/TRAIL.
Many studies have shown similar results but with fewer phosphorylated proteins
being examined. This report is among the first few to comprehensively examine the
molecular consequences of fisetin-facilitated modulation of phosphorylated proteins that
are associated with proliferation, apoptosis, oxidative stress, inflammation, invasion and
metastasis (Table 2) [23,25,51,54].
Table 2. Table showing fisetin-mediated modulation of various signalling pathways by altered
expression of different genes and phosphorylated proteins.
Hall Mark

Molecular Target

Transcript Expression
Upregulation
Downregulation

Protein Expression
Upregulation
Downregulation

MAPK

MAPK1, MAK14,
MAP2K1,
MAP2K6, ELK 1

p38
(P-Thr180/Tyr182)
and P53 (P-Ser15)

AKT/MTPR/PI3K

AKT2, MTOR,
PIK3C2B, PIK3CB.

p27 (P-Thr198)

Pathways:Antiproliferation,
anti-inflammation
and apoptosisinducing
pathway

JAK-STAT and
NF-kB

RSK1 (P-Ser380)
and Raf-1
(P-Ser301)
GSK3a (p-ser21),
GSK3b (p-ser9),
MTOR (p-ser2448),
PRAS 40
(p-Ther246), BAD
(p-ser112), PTEN
(p-ser380), AKT
(p-ser473), AMPKa
(P-Thr172), RPS6
(P-Ser235/236),
and 4E-BP1
(P-Thr36).
Src (P-Tyr419),
STAT1 (P-Ser727),
STAT2 (P-Tyr689),
STAT3 (P-Tyr705),
STAT5 (P-Tyr694),
TYK2 (P-Tyr1054),
HDAC4 (P-Ser632),
NF-kB (P-Ser536),
TAK1 (P-Ser412)
and TBK1
(P-Ser172).

The activated JAK–STAT pathway induces proliferation, cell survival and increases inflammation in cervical cancer. Activated JAK induces STAT phosphorylation and activation,
which then can translocate to the nucleus and acts as a transcription factor. Therefore, their
dephosphorylation will suppress the pathway [55,56]. The current study results demonstrate that fisetin treatment (50 µM) reduced or dephosphorylated STAT1 (P-Ser727), STAT2
(P-Tyr689), STAT3 (P-Tyr705), STAT5 (P-Tyr694) and TYK2 (P-Tyr1054) compared with the
control; therefore, it represses the pathway. SOCS (suppressors of cytokine signalling) also
regulates the activation of the JAK–STAT pathway [56]. This study showed an increased
fold change of SOCS 1, which can additionally suppress the JAK–STAT pathway.
Activating PI3K/AKT and MAPK pathways through phosphorylation deters apoptosis; however, dephosphorylation probably leads to cell death [57–59]. PI3K–Akt and
Ras–MAPK pathways congregate at BAD and mediate phosphorylation of BAD at two
separate serine residues, i.e., serine-112 (Ser-112) and serine-136 (Ser-136). These two sites
become phosphorylated by AKT and Ras–Raf (MAPK), respectively [12,60]. Phosphorylated BAD loses its ability to form a heterodimer with anti-apoptotic protein BCL-XL
or BCL-2; therefore, it binds with 14-3-3 and is impounded in the cytoplasm, whereas
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the dephosphorylated BAD associates with pro-survival protein (BCL-XL or BCL-2) and
accumulates in the mitochondrial membrane that subsequently upsurges apoptosis [12,60].
The AKT/PI3K pathway leads to activation of the mTOR and NF-κB pathways. Notably,
the activated Akt/PKB pathway inactivates pro-apoptotic genes such as Bad and caspase-9,
FOXO-tumour suppressor gene (forkhead family of transcription factors) and FASL (proapoptotic factor), thereby leading to tumorigenesis. Therefore, targeting the AKT/PI3K
pathway as a cancer therapy is currently employed to inhibit tumour progression [9,10,61].
In this study, fisetin treatment downregulated the AKT/PI3K/mTOR pathway by decreasing the expression of AKT2, MTOR, PIK3C2B and ELK 1 significantly, whereas PIK3CA
and PIK3CB expression were slightly reduced at the transcript level. Fisetin treatment
dephosphorylated various proteins involved in the AKT/PI3K/mTOR pathway, such as
GSK3a, GSK3b, MTOR, PRAS 40, BAD (p-ser112), PTEN (p-ser380), AKT (p-ser473) and
RPS6. In contrast, p27 (P-Thr198) expression was increased compared with the untreated
control HeLa cells (Table 2) (Figure 6A,B). Phosphatase activity of PTEN increases by dephosphorylation at Ser380 and it directly represses the PI3K/AKT pathway by conversion
of PIP3 back to PIP2 produced via PI3K [62]. Therefore, the result of this shows that fisetin
dephosphorylates PTEN to suppresses the AKT/PI3K pathway.
The MAPK pathway is primarily responsible for cell proliferation, differentiation
and cell survival. Ulixertinib BVD-523, a novel, reversible, ATP-competitive ERK1/2
inhibitor, has been reported to decrease cell growth and augment caspase activity in vitro.
Similarly, in an in vivo xenograft, it revealed concentration-dependent growth inhibition
and tumour regression. Fisetin brings about its anti-carcinogenic activity by substantial
downregulation of multiple molecular targets of the MAPK pathway such as MAPK1,
MAK14, MAP2K6, MAP3K5 and ELK 1, with marginal reduction in MAP2K1 expression,
whereas the expression of PTPRR (inhibitor of the MAPK pathway) was downregulated.
Consistent with the transcript level, fisetin also reduced phosphorylated protein expression
involved in the MAPK pathway. Certain proteins showed marginal alteration in fold
change such as ERK1/ERK2, RSK1(P-Ser380) and CREB (P-Ser133), while Raf-1 (P-Ser301)
showed a significant decrease. Phosphorylation levels of p38 (P-Thr180/Tyr182) and P53
(P-Ser15) were found to be significantly increased [8,35,63,64].
It was reported that p53 accumulation in protein levels induces phosphorylation of
P53 at Ser15 residue, which increases the apoptosis in cancer cells [65]. Consistent with
the previous reports, this study also established that fisetin upregulated both p53 and P53
(P-Ser15) expression. Polyphenol, such as luteolin and quercetin, have revealed a similar
effect on AKT and MAPK pathways (Table 2) [13,30].
Plant-derived polyphenols, including fisetin, were acknowledged to have significant
potential as an anti-carcinogenic candidate as they are capable of modulating multiple
signalling pathways associated with cancer. However, the activity of this compound
varies markedly in in vitro conditions when compared with in vivo responses. The low
bioavailability of this compound could feasibly explain variation in the action of fisetin due
to its hydrophobic nature. Several drug-loaded nanoparticles or micelle formulations have
been attempted to enhance the bioavailability of fisetin, and most of them have exhibited
higher anticancer efficacy than that of a fisetin solution alone [66–68]. Although most
of the work reported on fisetin is based on in vitro and in vivo studies, preclinical study
findings on the pharmacological properties of fisetin potentially demonstrate the necessity
of conducting suitably designed clinical trials for humans [15]. These studies will provide
definitive answers to the effectiveness of this appealing natural compound and offer new
possibilities for the forthcoming clinical applications of fisetin in the near future.
4. Materials and Methods
4.1. Cell lines and Reagents
HeLa cells (Human Cervical cancer) and AC-16 (Human cardiomyocyte), were gifted
from Dr Mawieh, Sharjah university, Sharjah. HeLa and AC-16 cells were maintained in
DMEM with 10% FBS (Sigma; St. Louis, MO, USA) with 1% penicillin and streptomycin pro-
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cured from Sigma (Sigma; St. Louis, MO, USA) in a humidified environment with 5% CO2
at a constant temperature of 37 ◦ C. 40 ,6-diamidino-2-phenylindole (DAPI), dimethyl sulfoxide (DMSO), propidium iodide (PI), 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium
(MTT) and trypsin-EDTA were obtained from Sigma Aldrich (Merck KGaA).
4.2. Preparation of Drug Solutions
Fisetin was procured from TOCRIS biosciences (Bristol, UK). In total, 69.87 mM fisetin
solution was prepared in dimethyl sulphoxide, and aliquots were stored at −20 ◦ C. Working
dilutions between 1–70 µM in range were made in complete media for treatment.
4.3. Cell Viability Assay
Cytotoxicity of fisetin on HeLa and AC-16 cells was evaluated by MTT (thiazolyl
blue tetrazolium bromide) assay. In total, ~1 × 104 cells/well were seeded in 96 well
plates and kept overnight at 37 ◦ C. Next, the treatment started for 24 and 48 h with
various concentrations of fisetin, i.e., 1, 10, 20, 30, 35, 40, 45, 50, 55, 60, 65 and 70 µM in
complete media on HeLa cells while the AC-16 cells (cardio myocyte) were treated with
several concentrations (1–400 µM) of fisetin for 24 h. All the treatments were conducted in
triplicates. After 24 h and 48 h treatment, 10 µL/well of MTT (Sigma, USA) with a final
concentration of 0.5 mg/mL in PBS was added to each well and incubated for 2–4 h at
37 ◦ C. Subsequently, 100 µL of DMSO was added in each well to dissolve the formazan
crystal. The absorbance reading was taken with Absorbance Microplate Reader (BioTek,
USA) at 570 nm. The % of cell viability was determined with the help of the given equation.
Cell viability (%) = (OD of treated groups)/(OD of control groups) × 100

(1)

The microscopic analysis of fisetin treated HeLa cells was evaluated by using an
inverted microscope (Labomed, Los Angeles, CA, USA).
4.4. Nuclear Morphology by DAPI (4,6-diamidino-2-phenylindile) Staining
HeLa cells (~3 × 104 cells/500 mL) were seeded in 24 well plates and kept overnight
at 37 ◦ C. After completing the treatment at two time points i.e., 24 and 48 h, respectively,
PBS wash of the cells was performed followed by fixing the cells with 70% ice-cold ethanol
for 20 min. Subsequently, the fixed cells were incubated with DAPI to stain the nucleus
(2.5 µg/mL of PBS) for 15 min in the dark, followed by an examination of nuclear morphology with the help of a fluorescent microscope. All the images were captured at ×20.
4.5. DNA Fragmentation Assay
Apoptosis induces nuclear DNA cleavage by nuclear endonuclease, which can be
analysed by agarose gel electrophoresis. DNA fragmentation assay was performed using
the Quick Apoptotic DNA Ladder Detection Kit by Ray biotech following manufacturer
protocol to affirm fisetin-mediated nuclear cleavage. Briefly, ~1 × 106 cells were plated
in each flask and treated with fisetin (0, 20, 30 and 50 µM for 48 h). Cells were gently
trypsinized and pelleted, followed by resuspension in lysis buffer. Then, the DNA was
precipitated by isopropanol alcohol. The DNA with the suspension buffer was subjected to
gel electrophoresis with 1.2% agarose comprising 0.5 mg/mL ethidium bromide in both
gel and running buffer. The gel was visualized under a UV light transilluminator.
4.6. Cell Cycle Analysis
Treated and untreated HeLa cells were used to analyse their DNA content using the
Propidium Iodide Flow Cytometry Kit from Abcam (ab139418, Cambridge, UK). A total of
~2 × 106 cells per concentration were treated with 0, 20, 30, and 50 µM of fisetin. It was
then followed by the respective time point treatment, i.e., the cells were harvested through
gentle trypsinization with 0.05% trypsin, fixed and kept overnight at −20 ◦ C. Then, the
cells were stained with PI as per the manufacturer’s protocol, followed by analysis for
various cell cycle phases using flow cytometer (FACS Calibur; Becton-Dickinson, Franklin
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Lakes, NJ, USA). Data were analysed by FlowJo, Software (FlowJo LLC; version 10.1). The
experiment has been repeated thrice.
4.7. Annexin V/Propidium Iodide Double Staining to Quantitate Apoptosis
The proportion of cells that have undergone apoptosis was determined by Annexin VFITC Apoptosis detection kits (ab14085, Cambridge, UK). Treated HeLa cells
(~2 × 105 cells/well in a six-well plate) at a concentration of 20, 30 and 50 µM at a time
point of 24 and 48 h were harvested and washed with PBS followed by staining with
Annexin–Pi for 20 min in a dark room. The early and late apoptotic cells were determined
by (FACS Calibur, Becton-Dickinson, Franklin Lakes, NJ, USA).
4.8. TMRE Staining to Analyse Mitochondrial Membrane Potential
TMRE (Tetramethylrhodamine, ethyl ester) dye was used to stain the live cell using
TMRE-Mitochondrial Potential assay kit from Abcam (ab113852; Cambridge, UK). The kit
was employed to analyse the impact of fisetin on alteration in mitochondrial membrane
potential. The assay was performed as per the kit’s protocol. Briefly, ~5 × 103 cells/well
was treated with 20, 30 and 50 µM of fisetin for 48 h followed by the addition of TMRE in
control and treated cells while FCCP was added to the negative control cells (FCCP prevents
staining by TMRE). The plate was then incubated at 37 ◦ C for 30 min, the fluorescence
reading was taken by using microplate spectrophotometry (Ex/Em = 549/575 nm) and
images were captured to examine the mitochondrial fluorescence intensity in treated
and untreated controls by a fluorescence microscope (Progress Fluorescent Microscope
Olympus, USA) at ×40.
4.9. Gene Expression by TaqMan Apoptosis Array
RNA was isolated from the treated (20, 30 and 50 µM for 48 h) and control cells
as per the kit’s protocol (Gen Elute Mammalian Genomic Total RNA Kit; Sigma, USA).
The qualitative check was performed by running the isolated RNA in 1% agarose gel
and the same was quantitated using nanodrop (Nanodrop 2000c; Thermo Scientific™,
Waltham, MA, USA). The RNA was used to synthesize cDNA with the help of a HighCapacity cDNA Reverse Transcription Kit (Applied Biosystems™, Waltham, MA USA)
as per the manufacturer’s instruction. TaqMan® Gene Expression Array and master mix
(Apoptosis Array, cat. No. 4414072 and 4369514) was employed to evaluate the expression
of various molecular targets involved in apoptosis and signalling pathways, including cell
proliferation, cell survival, etc. To each well of the assay plate, 10 µL of cDNA (100 ng/well)
from the treated cells, along with 10 µL of the master mix, was added. The plate was
then subjected to run for qPCR (QuantiStudio3; Applied Biosystems) and analysis was
performed by DataAssistTM software version 3.01 (ThermoFisher Scientific) with the
2− ∆∆Cq method. The expression level of GAPDH (a housekeeping gene) was used to
normalize the data. The RQ values display the fold change for the expression of various
genes in treated cells compared with the untreated control.
4.10. Measurement of Apoptosis-Related Proteins Expression by Proteome Profiler Array
Modulated manifestation of proteins pertaining to apoptosis after treatment with
20 µM and 50 µM fisetin was ascertained by RayBio® Human Apoptosis Arrays C1(Cat. No.
AAH-APO) and was compared with the untreated control. Firstly, protein quantitation was
conducted by Pierce BCA assay (Catalogue no: 23225; Thermo Fisher Scientific, USA). Each
nitrocellulose membrane was incubated with 500 µg of the diluted protein sample from
the lysate and kept overnight on a rocking platform at 4 ◦ C. Then, the membranes were
washed with wash buffers to discard any unbound proteins. Next, labelling was performed
with biotinylated antibody followed by signal development through HRP-Streptavidin.
It was then followed by thorough washing; the membranes were incubated with 500 µL
of detection buffer for 2 min at room temperature. Within 5 min, the membranes were
exposed to a chemiluminescent detection gel Doc device (Bio-Rad Laboratories; Richmond,
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CA, USA). The data analysis was conducted employing Image Lab software (version 6.0.1,
Bio-Rad, Hercules, CA, USA).
4.11. Phosphorylation Array
Modulated expression of a variety of phosphorylated proteins followed by 50 µM
fisetin treatment was evaluated by RayBio® Human Phosphorylation Pathway Profiling
Array C55 (AAH-PPP-1-2), and the expression of various molecular targets involved in
different pathways was correlated with the untreated control. The experiment was carried
out exactly as per the kit’s protocol, which was already explained under apoptosis array.
Data analysis was completed through image lab software, version 6.0.1 (Bio-Rad, Richmond,
CA, USA).
4.12. Caspases Multiplex Assay
To ascertain the type of apoptotic pathway employed by fisetin to induce cell death,
caspase multiplex (Caspase 3, 8 and 9) assay was performed. The caspase multiplex
assay kit (fluorometric) was obtained from Abcam (ab219915; Cambridge, UK), and the
assay was completed according to the kit’s protocol. Briefly, ~8 × 103 cells/per well were
seeded in 96 well plate followed by treatment with various concentrations of fisetin (20,
30 and 50 µM) for 48 h. All treatments were performed in triplicates. After treatment,
each well was incubated with 100 µL of caspase substrate (for all three caspases) for 1 h.
Fluorescence reading was measured at wavelengths between 370–620 nm, followed by fold
change calculation.
4.13. Detection of GSH Activity in HeLa Cells
To establish if fisetin treatment alleviates the oxidative stress in HeLa cells, a GSH
assay was carried out. The GSH assay kit (colorimetric) was procured from Biovision
(Catalog #K261) and was completed as per the manufacturer’s protocol. Briefly, the treated
cells (20, 30 and 50 µM) and untreated control cells were collected in ice-cold PBS followed
by lysis with glutathione buffer. Then 5% SSA (sulfosalicylic acid) was added and subjected
to centrifuge at 8000× g for 10 min. Supernatant was used for glutathione assay. Then,
the 96 well plate was incubated for 10 min at RT with 160 µL of reaction mix to generate
NADPH followed by the addition of 20 µL of each sample solution and substrate. After the
incubation, an absorbance reading was taken at 405 nm and GSH activity was calculated.
4.14. Inflammation Array
To validate the anti-inflammatory role of fisetin, modulated expression of different antiinflammatory proteins after fisetin treatment at 50 µM was compared with the untreated
control. Human inflammation antibody array was carried out, which was procured from
Abcam (ab134003; Cambridge, UK). To perform the array, firstly, protein quantitation of the
cell lysate was performed by BCA assay. After blocking the membrane by blocking buffer
for 30 min, each membrane was incubated with ~250 µg of lysate overnight on a rocking
platform at 4 ◦ C, followed by washing with wash buffer I and II to discard any unbound
proteins. After the washes, the nitrocellulose membranes were labelled with biotinylated
antibody. Finally, HRP-Streptavidin was added and left on the rocking surface for 2 h
followed by washing and the subsequent addition of 500 µL detection buffer mixture C
and D. Within 5 min, the membrane was exposed to chemiluminescent detector gel doc
system (Bio-Rad Laboratories, Richmond, California, USA). Image Lab software, version
6.0.1, Bio-Rad was used to analyse the data.
4.15. Statistical Analysis
Data were analysed by using the GraphPad prism program (version 9.2.0) with either
one-way or two-way analyses of variance, followed by Tukey’s HSD post-hoc test. All
the data have been expressed as mean ± SD of at least 3 experiments. p-value < 0.05 was
considered statistically significant.
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5. Conclusions
The current study results reveal that fisetin modifies PI3K/AKT, MAPK, TGF-β/WNT,
JAK-STAT and NF-kB pathways by modulating the expression of multiple molecular targets
at both transcript and proteins levels. Modulation in expression of different proteins leads
to cell growth inhibition, cell cycle arrest, DNA damage, attenuating oxidative stress and
alleviating inflammation, inducing apoptosis. The current study establishes clear evidence
about the multifaceted role of fisetin as an anticancer agent with its differential action
towards tumour and normal cells; therefore, a safer profile [69].
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